GrippeCanadaV3, Main, Exploration, bibRecord, 000002

Effect of seasonal influenza vaccination on influenza symptom severity among children in Hutterite communities: Follow-up study of a randomized trial.

Identifieur interne : 000002 ( Main/Exploration ); précédent : 000001; suivant : 000003

Effect of seasonal influenza vaccination on influenza symptom severity among children in Hutterite communities: Follow-up study of a randomized trial.

Auteurs : Shannon E. Brent [Canada] ; Eleanor Pullenayegum [Canada] ; Margaret L. Russell [Canada] ; Mark Loeb [Canada]

Source :

Influenza and other respiratory viruses [ 1750-2659 ] ; 2020.

RBID : pubmed:31702876

Descripteurs français

KwdFr :
- Adolescent, Alberta, Enfant, Enfant d'âge préscolaire, Femelle, Grippe humaine (), Grippe humaine (diagnostic), Grippe humaine (virologie), Humains, Mâle, Saisons, Sous-type H1N1 du virus de la grippe A (génétique), Sous-type H1N1 du virus de la grippe A (immunologie), Sous-type H1N1 du virus de la grippe A (physiologie), Vaccination, Vaccins antigrippaux (administration et posologie), Vaccins inactivés (administration et posologie), Virus influenza B (génétique), Virus influenza B (immunologie), Virus influenza B (physiologie), Études de suivi, Études rétrospectives.
MESH :
- administration et posologie : Vaccins antigrippaux, Vaccins inactivés.
- diagnostic : Grippe humaine.
- génétique : Sous-type H1N1 du virus de la grippe A, Virus influenza B.
- immunologie : Sous-type H1N1 du virus de la grippe A, Virus influenza B.
- physiologie : Sous-type H1N1 du virus de la grippe A, Virus influenza B.
- virologie : Grippe humaine.
- Adolescent, Alberta, Enfant, Enfant d'âge préscolaire, Femelle, Grippe humaine, Humains, Mâle, Saisons, Vaccination, Études de suivi, Études rétrospectives.

English descriptors

KwdEn :
- Adolescent, Alberta, Child, Child, Preschool, Female, Follow-Up Studies, Humans, Influenza A Virus, H1N1 Subtype (genetics), Influenza A Virus, H1N1 Subtype (immunology), Influenza A Virus, H1N1 Subtype (physiology), Influenza B virus (genetics), Influenza B virus (immunology), Influenza B virus (physiology), Influenza Vaccines (administration & dosage), Influenza, Human (diagnosis), Influenza, Human (prevention & control), Influenza, Human (virology), Male, Retrospective Studies, Seasons, Vaccination, Vaccines, Inactivated (administration & dosage).
MESH :
- chemical , administration & dosage : Influenza Vaccines, Vaccines, Inactivated.
- geographic : Alberta.
- diagnosis : Influenza, Human.
- genetics : Influenza A Virus, H1N1 Subtype, Influenza B virus.
- immunology : Influenza A Virus, H1N1 Subtype, Influenza B virus.
- physiology : Influenza A Virus, H1N1 Subtype, Influenza B virus.
- prevention & control : Influenza, Human.
- virology : Influenza, Human.
- Adolescent, Child, Child, Preschool, Female, Follow-Up Studies, Humans, Male, Retrospective Studies, Seasons, Vaccination.

Abstract

BACKGROUND

We investigated whether influenza vaccination reduces symptom severity among children who develop laboratory-confirmed influenza, and whether this association differed between influenza vaccine formulations.

METHODS

We performed a retrospective cohort study using data from two blinded cluster randomized control trials of influenza vaccines in Hutterite colonies. In trial 1, children received trivalent inactivated influenza vaccine (TIV) or hepatitis A vaccine. In trial 2, children received trivalent live attenuated (TLAIV) or TIV. We assessed four outcomes (total number of symptoms, number of respiratory symptoms, number of systemic symptoms, and duration of symptoms) among children with PCR-confirmed influenza. We utilized two-sample t tests to quantify the relationship between vaccine group and outcome. We performed multivariable strain-specific analyses, controlling for age and season.

RESULTS

TIV vs. Hep A vaccine: Among vaccinated children, 200 confirmed influenza infections were observed across 3014 person-seasons. Vaccine type (TIV vs. Hep A vaccine) did not significantly affect the number of respiratory or systemic symptoms, nor duration of symptoms (P > .05). TLAIV vs. TIV: Among 1186 children who received a study vaccine, 166 confirmed influenza infections were observed. TLAIV recipients experienced fewer total, respiratory, and systemic symptoms compared to TIV recipients (P < .05 for all). TLAIV-associated attenuation of symptom severity was observed in influenza B or A/H1N1 infections, but not H3.

CONCLUSIONS

Seasonal influenza vaccine did not consistently attenuate symptom severity in the context of vaccine failure; however, TLAIV offered superior severity attenuation compared to TIV. Our results challenge the dictum that influenza vaccine reduces the severity of symptoms even when the vaccine fails to prevent influenza.

DOI: 10.1111/irv.12689
PubMed: 31702876

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000002
to stream Main, to step Curation: 000002

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of seasonal influenza vaccination on influenza symptom severity among children in Hutterite communities: Follow-up study of a randomized trial.</title>
<author><name sortKey="Brent, Shannon E" sort="Brent, Shannon E" uniqKey="Brent S" first="Shannon E" last="Brent">Shannon E. Brent</name>
<affiliation wicri:level="4"><nlm:affiliation>Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON</wicri:regionArea>
<orgName type="university">Université McMaster</orgName>
<placeName><settlement type="city">Hamilton (Ontario)</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pullenayegum, Eleanor" sort="Pullenayegum, Eleanor" uniqKey="Pullenayegum E" first="Eleanor" last="Pullenayegum">Eleanor Pullenayegum</name>
<affiliation wicri:level="4"><nlm:affiliation>The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>The Hospital for Sick Children, University of Toronto, Toronto, ON</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Russell, Margaret L" sort="Russell, Margaret L" uniqKey="Russell M" first="Margaret L" last="Russell">Margaret L. Russell</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Community Health Sciences, Cumming School of Medicine, The University of Calgary, Calgary, AB, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Community Health Sciences, Cumming School of Medicine, The University of Calgary, Calgary, AB</wicri:regionArea>
<orgName type="university">Université de Calgary</orgName>
<placeName><settlement type="city">Calgary</settlement>
<region type="state">Alberta</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Loeb, Mark" sort="Loeb, Mark" uniqKey="Loeb M" first="Mark" last="Loeb">Mark Loeb</name>
<affiliation wicri:level="4"><nlm:affiliation>Departments of Pathology and Molecular Medicine and Health Research Evidence and Impact, Institute for Infectious Disease Research, McMaster University, Hamilton, ON, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Departments of Pathology and Molecular Medicine and Health Research Evidence and Impact, Institute for Infectious Disease Research, McMaster University, Hamilton, ON</wicri:regionArea>
<orgName type="university">Université McMaster</orgName>
<placeName><settlement type="city">Hamilton (Ontario)</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:31702876</idno>
<idno type="pmid">31702876</idno>
<idno type="doi">10.1111/irv.12689</idno>
<idno type="wicri:Area/Main/Corpus">000002</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000002</idno>
<idno type="wicri:Area/Main/Curation">000002</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000002</idno>
<idno type="wicri:Area/Main/Exploration">000002</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Effect of seasonal influenza vaccination on influenza symptom severity among children in Hutterite communities: Follow-up study of a randomized trial.</title>
<author><name sortKey="Brent, Shannon E" sort="Brent, Shannon E" uniqKey="Brent S" first="Shannon E" last="Brent">Shannon E. Brent</name>
<affiliation wicri:level="4"><nlm:affiliation>Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON</wicri:regionArea>
<orgName type="university">Université McMaster</orgName>
<placeName><settlement type="city">Hamilton (Ontario)</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pullenayegum, Eleanor" sort="Pullenayegum, Eleanor" uniqKey="Pullenayegum E" first="Eleanor" last="Pullenayegum">Eleanor Pullenayegum</name>
<affiliation wicri:level="4"><nlm:affiliation>The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>The Hospital for Sick Children, University of Toronto, Toronto, ON</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Russell, Margaret L" sort="Russell, Margaret L" uniqKey="Russell M" first="Margaret L" last="Russell">Margaret L. Russell</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Community Health Sciences, Cumming School of Medicine, The University of Calgary, Calgary, AB, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Community Health Sciences, Cumming School of Medicine, The University of Calgary, Calgary, AB</wicri:regionArea>
<orgName type="university">Université de Calgary</orgName>
<placeName><settlement type="city">Calgary</settlement>
<region type="state">Alberta</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Loeb, Mark" sort="Loeb, Mark" uniqKey="Loeb M" first="Mark" last="Loeb">Mark Loeb</name>
<affiliation wicri:level="4"><nlm:affiliation>Departments of Pathology and Molecular Medicine and Health Research Evidence and Impact, Institute for Infectious Disease Research, McMaster University, Hamilton, ON, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Departments of Pathology and Molecular Medicine and Health Research Evidence and Impact, Institute for Infectious Disease Research, McMaster University, Hamilton, ON</wicri:regionArea>
<orgName type="university">Université McMaster</orgName>
<placeName><settlement type="city">Hamilton (Ontario)</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Influenza and other respiratory viruses</title>
<idno type="eISSN">1750-2659</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Alberta</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Influenza A Virus, H1N1 Subtype (genetics)</term>
<term>Influenza A Virus, H1N1 Subtype (immunology)</term>
<term>Influenza A Virus, H1N1 Subtype (physiology)</term>
<term>Influenza B virus (genetics)</term>
<term>Influenza B virus (immunology)</term>
<term>Influenza B virus (physiology)</term>
<term>Influenza Vaccines (administration & dosage)</term>
<term>Influenza, Human (diagnosis)</term>
<term>Influenza, Human (prevention & control)</term>
<term>Influenza, Human (virology)</term>
<term>Male</term>
<term>Retrospective Studies</term>
<term>Seasons</term>
<term>Vaccination</term>
<term>Vaccines, Inactivated (administration & dosage)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term>
<term>Alberta</term>
<term>Enfant</term>
<term>Enfant d'âge préscolaire</term>
<term>Femelle</term>
<term>Grippe humaine ()</term>
<term>Grippe humaine (diagnostic)</term>
<term>Grippe humaine (virologie)</term>
<term>Humains</term>
<term>Mâle</term>
<term>Saisons</term>
<term>Sous-type H1N1 du virus de la grippe A (génétique)</term>
<term>Sous-type H1N1 du virus de la grippe A (immunologie)</term>
<term>Sous-type H1N1 du virus de la grippe A (physiologie)</term>
<term>Vaccination</term>
<term>Vaccins antigrippaux (administration et posologie)</term>
<term>Vaccins inactivés (administration et posologie)</term>
<term>Virus influenza B (génétique)</term>
<term>Virus influenza B (immunologie)</term>
<term>Virus influenza B (physiologie)</term>
<term>Études de suivi</term>
<term>Études rétrospectives</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term>
<term>Vaccines, Inactivated</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>Alberta</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term>
<term>Vaccins inactivés</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term>
<term>Influenza B virus</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term>
<term>Virus influenza B</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term>
<term>Virus influenza B</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term>
<term>Influenza B virus</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term>
<term>Virus influenza B</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term>
<term>Influenza B virus</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Male</term>
<term>Retrospective Studies</term>
<term>Seasons</term>
<term>Vaccination</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term>
<term>Alberta</term>
<term>Enfant</term>
<term>Enfant d'âge préscolaire</term>
<term>Femelle</term>
<term>Grippe humaine</term>
<term>Humains</term>
<term>Mâle</term>
<term>Saisons</term>
<term>Vaccination</term>
<term>Études de suivi</term>
<term>Études rétrospectives</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b>
</p>
<p>We investigated whether influenza vaccination reduces symptom severity among children who develop laboratory-confirmed influenza, and whether this association differed between influenza vaccine formulations.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>METHODS</b>
</p>
<p>We performed a retrospective cohort study using data from two blinded cluster randomized control trials of influenza vaccines in Hutterite colonies. In trial 1, children received trivalent inactivated influenza vaccine (TIV) or hepatitis A vaccine. In trial 2, children received trivalent live attenuated (TLAIV) or TIV. We assessed four outcomes (total number of symptoms, number of respiratory symptoms, number of systemic symptoms, and duration of symptoms) among children with PCR-confirmed influenza. We utilized two-sample t tests to quantify the relationship between vaccine group and outcome. We performed multivariable strain-specific analyses, controlling for age and season.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>RESULTS</b>
</p>
<p>TIV vs. Hep A vaccine: Among vaccinated children, 200 confirmed influenza infections were observed across 3014 person-seasons. Vaccine type (TIV vs. Hep A vaccine) did not significantly affect the number of respiratory or systemic symptoms, nor duration of symptoms (P > .05). TLAIV vs. TIV: Among 1186 children who received a study vaccine, 166 confirmed influenza infections were observed. TLAIV recipients experienced fewer total, respiratory, and systemic symptoms compared to TIV recipients (P < .05 for all). TLAIV-associated attenuation of symptom severity was observed in influenza B or A/H1N1 infections, but not H3.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b>
</p>
<p>Seasonal influenza vaccine did not consistently attenuate symptom severity in the context of vaccine failure; however, TLAIV offered superior severity attenuation compared to TIV. Our results challenge the dictum that influenza vaccine reduces the severity of symptoms even when the vaccine fails to prevent influenza.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31702876</PMID>
<DateCompleted><Year>2020</Year>
<Month>05</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>05</Month>
<Day>28</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1750-2659</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>14</Volume>
<Issue>1</Issue>
<PubDate><Year>2020</Year>
<Month>01</Month>
</PubDate>
</JournalIssue>
<Title>Influenza and other respiratory viruses</Title>
<ISOAbbreviation>Influenza Other Respir Viruses</ISOAbbreviation>
</Journal>
<ArticleTitle>Effect of seasonal influenza vaccination on influenza symptom severity among children in Hutterite communities: Follow-up study of a randomized trial.</ArticleTitle>
<Pagination><MedlinePgn>28-36</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/irv.12689</ELocationID>
<Abstract><AbstractText Label="BACKGROUND">We investigated whether influenza vaccination reduces symptom severity among children who develop laboratory-confirmed influenza, and whether this association differed between influenza vaccine formulations.</AbstractText>
<AbstractText Label="METHODS">We performed a retrospective cohort study using data from two blinded cluster randomized control trials of influenza vaccines in Hutterite colonies. In trial 1, children received trivalent inactivated influenza vaccine (TIV) or hepatitis A vaccine. In trial 2, children received trivalent live attenuated (TLAIV) or TIV. We assessed four outcomes (total number of symptoms, number of respiratory symptoms, number of systemic symptoms, and duration of symptoms) among children with PCR-confirmed influenza. We utilized two-sample t tests to quantify the relationship between vaccine group and outcome. We performed multivariable strain-specific analyses, controlling for age and season.</AbstractText>
<AbstractText Label="RESULTS">TIV vs. Hep A vaccine: Among vaccinated children, 200 confirmed influenza infections were observed across 3014 person-seasons. Vaccine type (TIV vs. Hep A vaccine) did not significantly affect the number of respiratory or systemic symptoms, nor duration of symptoms (P > .05). TLAIV vs. TIV: Among 1186 children who received a study vaccine, 166 confirmed influenza infections were observed. TLAIV recipients experienced fewer total, respiratory, and systemic symptoms compared to TIV recipients (P < .05 for all). TLAIV-associated attenuation of symptom severity was observed in influenza B or A/H1N1 infections, but not H3.</AbstractText>
<AbstractText Label="CONCLUSIONS">Seasonal influenza vaccine did not consistently attenuate symptom severity in the context of vaccine failure; however, TLAIV offered superior severity attenuation compared to TIV. Our results challenge the dictum that influenza vaccine reduces the severity of symptoms even when the vaccine fails to prevent influenza.</AbstractText>
<CopyrightInformation>© 2019 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brent</LastName>
<ForeName>Shannon E</ForeName>
<Initials>SE</Initials>
<AffiliationInfo><Affiliation>Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pullenayegum</LastName>
<ForeName>Eleanor</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Russell</LastName>
<ForeName>Margaret L</ForeName>
<Initials>ML</Initials>
<AffiliationInfo><Affiliation>Department of Community Health Sciences, Cumming School of Medicine, The University of Calgary, Calgary, AB, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Loeb</LastName>
<ForeName>Mark</ForeName>
<Initials>M</Initials>
<Identifier Source="ORCID">0000-0003-2315-5390</Identifier>
<AffiliationInfo><Affiliation>Departments of Pathology and Molecular Medicine and Health Research Evidence and Impact, Institute for Infectious Disease Research, McMaster University, Hamilton, ON, Canada.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><Agency>CIHR</Agency>
<Country>Canada</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2019</Year>
<Month>11</Month>
<Day>08</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Influenza Other Respir Viruses</MedlineTA>
<NlmUniqueID>101304007</NlmUniqueID>
<ISSNLinking>1750-2640</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000416" MajorTopicYN="N" Type="Geographic">Alberta</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009981" MajorTopicYN="N">Influenza B virus</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012621" MajorTopicYN="N">Seasons</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">influenza</Keyword>
<Keyword MajorTopicYN="Y">randomized trial</Keyword>
<Keyword MajorTopicYN="Y">vaccination</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year>
<Month>05</Month>
<Day>29</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2019</Year>
<Month>09</Month>
<Day>11</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2019</Year>
<Month>09</Month>
<Day>12</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2019</Year>
<Month>11</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>5</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2019</Year>
<Month>11</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">31702876</ArticleId>
<ArticleId IdType="doi">10.1111/irv.12689</ArticleId>
<ArticleId IdType="pmc">PMC6928063</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>BMC Infect Dis. 2014 May 01;14:231</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24884932</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2014 Sep 29;32(43):5546-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25131746</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Infect Dis. 2017 Dec 8;17(1):757</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29216845</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2013 Dec 26;369(26):2481-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24328444</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2010 Mar 10;303(10):943-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20215608</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2018 Mar 31;391(10127):1285-1300</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29248255</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pediatr Infect Dis J. 2014 Feb;33(2):e63-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24061274</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2016 Dec 15;11(12):e0167281</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27977707</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Invest. 1998 Feb 1;101(3):643-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9449698</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccines (Basel). 2018 May 21;6(2):null</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29883414</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2017 Oct 15;65(8):1289-1297</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28525597</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pediatr Infect Dis J. 2006 Oct;25(10):870-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17006279</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2017 Dec 19;35(52):7297-7301</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29146382</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Intern Med. 2016 Nov 1;165(9):617-624</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27538259</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2007 Feb 15;356(7):685-96</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17301299</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2012 Jan;12(1):36-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22032844</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2015 Dec 16;33(51):7160-7167</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26562321</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Family Med Prim Care. 2016 Jan-Mar;5(1):7-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27453836</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2018 Apr 17;13(4):e0195611</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29664931</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Can Commun Dis Rep. 2011 Oct 14;37(ACS-5):1-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31682646</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Med. 2010 Apr 06;7(4):e1000258</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20386731</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2011 Mar 15;52(6):831-2; author reply 832-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21367740</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Canada</li>
</country>
<region><li>Alberta</li>
<li>Ontario</li>
</region>
<settlement><li>Calgary</li>
<li>Hamilton (Ontario)</li>
<li>Toronto</li>
</settlement>
<orgName><li>Université McMaster</li>
<li>Université de Calgary</li>
<li>Université de Toronto</li>
</orgName>
</list>
<tree><country name="Canada"><region name="Ontario"><name sortKey="Brent, Shannon E" sort="Brent, Shannon E" uniqKey="Brent S" first="Shannon E" last="Brent">Shannon E. Brent</name>
</region>
<name sortKey="Loeb, Mark" sort="Loeb, Mark" uniqKey="Loeb M" first="Mark" last="Loeb">Mark Loeb</name>
<name sortKey="Pullenayegum, Eleanor" sort="Pullenayegum, Eleanor" uniqKey="Pullenayegum E" first="Eleanor" last="Pullenayegum">Eleanor Pullenayegum</name>
<name sortKey="Russell, Margaret L" sort="Russell, Margaret L" uniqKey="Russell M" first="Margaret L" last="Russell">Margaret L. Russell</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeCanadaV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000002 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000002 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    GrippeCanadaV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:31702876
   |texte=   Effect of seasonal influenza vaccination on influenza symptom severity among children in Hutterite communities: Follow-up study of a randomized trial.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:31702876" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a GrippeCanadaV3

This area was generated with Dilib version V0.6.35.
Data generation: Tue Jul 7 13:36:58 2020. Site generation: Sat Sep 26 07:06:42 2020

	Corpus GrippeCanadaV3
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Corpus GrippeCanadaV3

Effect of seasonal influenza vaccination on influenza symptom severity among children in Hutterite communities: Follow-up study of a randomized trial.

Effect of seasonal influenza vaccination on influenza symptom severity among children in Hutterite communities: Follow-up study of a randomized trial.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki